Elsevier

Annals of Oncology

Volume 30, Supplement 2, April 2019, Pages ii48-ii49
Annals of Oncology

Submitted abstracts
Advanced NSCLC
113O - Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001

https://doi.org/10.1093/annonc/mdz063.011Get rights and content
Under an Elsevier user license
open archive

Cited by (0)